Novo Nordisk plunges 8.2% premarket as Ciltibekimap phase 3 fails
NVO Novo Nordisk ADR
$51.61 +0.06%
차트·분석 보기 → - 1Novo Nordisk (NVO) dives premarket after its Ciltibekimap phase 3 trial failed to show a significant reduction in major cardiovascular events versus placebo
- 2The experimental therapy demonstrated biological activity but missed its primary endpoint, sending shares down 8.2% in premarket trading
- 3The five-day winning streak is expected to end, with losses likely turning shares negative year-to-date and year-over-year if the decline holds
This 3-line summary is compiled from the report below.
Schaeffer's Research +7 View original ↗🎯 오늘의 AI 픽 5종목, 무료로 전부 공개합니다
숨기는 것 없이 — 지난 픽의 성적표(S&P500 대비)까지 그대로 보여드립니다